Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study.

Autor: Sfikakis PP; Department of Propedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, 17 Agiou Thoma Str., 115 27, Athens, Greece. psfikakis@med.uoa.gr.; Medical School, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, 75 Mikras Asias Street, 115 27, Athens, Greece. psfikakis@med.uoa.gr., Vassilopoulos D; Medical School, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, 75 Mikras Asias Street, 115 27, Athens, Greece.; Department of Medicine and Clinical Immunology-Rheumatology Unit, Medical School, National and Kapodistrian University of Athens, 114 Vass. Sophias Ave., 115 27, Athens, Greece., Katsifis G; Naval Hospital of Athens, 70 Dinokratous Str., 115 21, Athens, Greece., Vosvotekas G; Euromedica General Clinic of Thessaloniki, 11 Maria Kallas Str., 546 45, Thessaloniki, Greece., Dimitroulas T; Department of Internal Medicine, Medical School, Hippokration Hospital, Aristotle University of Thessaloniki, 49 Konstantinoupoleos Str., 546 42, Thessaloniki, Greece., Sidiropoulos P; Rheumatology, Clinical Immunology and Allergy, Medical School, University of Crete, Voutes, Crete, 711 10, Heraklion, Greece., Vounotrypidis P; Department of Rheumatology, 424 General Army Hospital, Nea Efkarpia, 564 29, Thessaloniki, Greece., Bogdanos DP; Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, University of Thessaly, Mezourlo, 411 10, Larissa, Greece., Georgountzos AΙ; General Hospital of Athens G. Gennimatas, 154 Mesogeion Ave., 115 27, Athens, Greece., Bounas AG; Olympion Private General Clinic of Patras, Volou & Meilichou Str., 264 43, Patras, Greece., Georgiou P; Rheumatology Unit, Agios Andreas Hospital, 37 Kalavriton Str., 263 32, Patras, Greece., Gazi S; Department of Rheumatology, KAT General Hospital of Attica, 2 Nikis Str., Kifissia, 145 61, Athens, Greece., Kataxaki E; Rheumatology Unit, Thriasio General Hospital of Elefsina, G. Gennimata Ave., 196 00, Magoula, Greece., Liossis SN; Division of Rheumatology, Department of Internal Medicine, Medical School, Patras University Hospital, University of Patras, Rio Achaia, 265 04, Patras, Greece., Theodorou E; Rheumatology Clinic 251 Hellenic Air Force Hospital, 3 Panagioti Kanellopoulou Ave., 115 25, Athens, Greece., Papagoras C; First Department of Internal Medicine, Medical School, University Hospital of Alexandroupolis, Democritus University of Thrace, 681 00, Alexandroupolis, Greece., Theotikos E; Rheumatology Department, Asklepieion Voulas General Hospital, 1 Vasileos Pavlou Ave, 166 73, Athens, Greece., Vlachoyiannopoulos P; Medical School, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, 75 Mikras Asias Street, 115 27, Athens, Greece.; Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, 17 Agiou Thoma Str., 115 27, Athens, Greece., Voulgari PV; Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, 451 10, Ioannina, Greece., Kekki A; Genesis Pharma SA, Athens, 274 Kifissias Ave., 152 32, Halandri, Greece., Antonakopoulos N; Genesis Pharma SA, Athens, 274 Kifissias Ave., 152 32, Halandri, Greece., Boumpas DT; Medical School, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, 75 Mikras Asias Street, 115 27, Athens, Greece.; Department of Internal Medicine, Medical School, 'Attikon' University Hospital, Athens, National and Kapodistrian University of Athens, 1 Rimini Str., 124 62, Athens, Greece.
Jazyk: angličtina
Zdroj: Rheumatology international [Rheumatol Int] 2023 May; Vol. 43 (5), pp. 889-902. Date of Electronic Publication: 2023 Mar 01.
DOI: 10.1007/s00296-022-05269-z
Abstrakt: To evaluate the effect of the phosphodiesterase 4 inhibitor apremilast in biologic-naïve patients with early peripheral PsA in terms of disease activity, clinical manifestations, patient-perceived outcomes, as well as apremilast's safety profile in routine care settings of Greece. Non-interventional, multicenter, 52-week prospective cohort study, enrolling biologic-naïve patients with early active peripheral PsA who started apremilast after intolerance or inadequate response (within the first 12 months of treatment) to an initial conventional synthetic (cs)DMARD treatment. Non-responder imputation was applied for missing data.In total, 167 consecutive patients (mean age: 52.5 years; median PsA duration: 0.9 years) were analyzed. At baseline, the median (interquartile range) clinical Disease Activity in Psoriatic Arthritis (cDAPSA) score was 22.0 (16.0-29.0), with 86.8% of patients having at least moderate (29.3% high) disease activity; 87.4% had skin psoriasis, 37.7% nail psoriasis, 30.7% enthesitis, and 12.4% dactylitis. At 16, 24, and 52 weeks, 28.7, 42.5, and 48.5% of patients, achieved ≥ 50% improvement in their baseline cDAPSA score, respectively. At week 52, 55.6, 50, and 26.8% of evaluable patients achieved complete resolution of enthesitis, dactylitis and nail psoriasis, respectively. Improvements were also observed in patient's health state assessed by the Psoriatic Arthritis Impact of Disease 12-item questionnaire, and health-related quality of life. The 52-week drug survival rate was 75%, while 13.8% of patients experienced at least one adverse drug reaction.Biologic-naïve patients with early PsA, treated with apremilast experienced significant improvements in disease activity, extra-articular manifestations and patient-centered outcomes, accompanied by a favorable tolerability profile.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: